In this study we extended our observations on the role of M1 and M2 muscarinic receptors in mediating the cholinergic induction of REM sleep. Cats were chronically implanted with sleep recording electrodes and microinjections of Ringer's or muscarinic antagonists followed by the relatively specific M2 muscarinic agonist, cis-methyl-dioxolane (cisdioxo), were made into the medial pontine reticular formation (mPRF). The microinjection of Ringer's followed by cisdioxo significantly increased REM sleep percentage. Atropine, a mixed muscarinic receptor antagonist, administered before cisdioxo blocked the REM sleep increase while pirenzepine, a selective M1 muscarinic antagonist, did not block the cisdioxo-induced increase in REM sleep. Gallamine, a nicotinic and a putative M2 antagonist, tended to inhibit the cisdioxo-induced increase in REM sleep. These results support the hypothesis that the cholinergic stimulation-induced REM sleep in the medial pontine reticular formation is mediated by a non-M1 muscarinic receptor subtype.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0006-8993(91)91064-8 | DOI Listing |
Alzheimers Dement
January 2025
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
Introduction: Sleep disturbances are associated with Alzheimer's disease (AD) and Alzheimer's disease and related dementias (ADRD), but the relationship between sleep architecture, particularly rapid eye movement (REM) sleep, and AD/ADRD biomarkers remains unclear.
Methods: We enrolled 128 adults (64 with Alzheimer's disease, 41 with mild cognitive impairment [MCI], and 23 with normal cognition [NC]), mean age 70.8 ± 9.
Study Objectives: Sleep deficiency is associated with Alzheimer's disease (AD) pathogenesis. We examined the association of sleep architecture with anatomical features observed in AD: (1) atrophy of hippocampus, entorhinal, inferior parietal, parahippocampal, precuneus, and cuneus regions ("AD-vulnerable regions") and (2) cerebral microbleeds.
Methods: In 271 participants of the Atherosclerosis Risk in the Communities Study, we examined the association of baseline sleep architecture with anatomical features identified on brain MRI 13∼17 years later.
Alzheimers Res Ther
January 2025
Fraunhofer Institute for Algorithms and Scientific Computing SCAI, Sankt Augustin, Germany.
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting millions worldwide, leading to cognitive and functional decline. Early detection and intervention are crucial for enhancing the quality of life of patients and their families. Remote Monitoring Technologies (RMTs) offer a promising solution for early detection by tracking changes in behavioral and cognitive functions, such as memory, language, and problem-solving skills.
View Article and Find Full Text PDFRes Dev Disabil
January 2025
School of Psychological Science, Oregon State University, 2950 SW Jefferson Way, Corvallis, OR 97331, USA. Electronic address:
Introduction: Moebius syndrome is a rare congenital disorder with frequent anecdotal reports of sleep disturbances not sufficiently categorized by prior literature. The present mixed-methods, two-phase study aimed to characterize the sleep health and symptoms of a cohort of adults and children (via parent proxies) with Moebius syndrome.
Methods: In Phase 1, participants were 46 adults with Moebius Syndrome (M=33.
Parkinsonism Relat Disord
January 2025
Department of Nuclear Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address:
Introduction: In isolated REM sleep behavior disorder (iRBD), the evidence of cognitive impairment and co-existing amyloid pathology suggests that mild behavioral impairment (MBI) may be associated with disease progression. In this study, we investigated MBI and its association with cognitive function, brain amyloid load and glucose metabolism in iRBD patients to evaluate the utility of MBI as a predictive marker of disease progression.
Methods: Patients with iRBD underwent a neuropsychological evaluation, F-florbetaben (FBB) PET, and F-fluorodeoxyglucose (FDG) PET.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!